Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Metabolic Effects of Androgenicity in Aging Men and Women

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00680797
First received: May 8, 2008
Last updated: February 7, 2014
Last verified: February 2014

May 8, 2008
February 7, 2014
January 2005
December 2012   (final data collection date for primary outcome measure)
Insulin Sensitivity [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00680797 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Metabolic Effects of Androgenicity in Aging Men and Women
Metabolic Effects of Androgenicity in Aging Men and Women

The goal of this research study is to study the effect of testosterone or estrogen on blood sugar control and fat metabolism. Changes in hormone levels with age may affect risk factors for heart disease such as diabetes. Diabetes is a glandular condition associated with lack of the hormone insulin or an insensitivity to it resulting in problems with blood sugar control and fat metabolism. The effect of commonly used hormonal supplements such as testosterone by older adults on insulin and body composition is not well understood. In this study, the role of testosterone and estrogen on your ability to control blood sugar and your body composition will be assessed.

We plan to study 60 subjects. All of these subjects will be healthy older men between the ages of 60-85 years old who are not on testosterone therapy. Subjects that are screened who have any clinically significant abnormalities detected on their screening physical exam or laboratory testing (e.g. PSA > 4), who have a history of prostate cancer, polycythemia, or who cannot take testosterone will not be included.

If a subject is eligible to participate after initial screening, that subject will take medications to adjust their hormone levels and have tests performed that measure insulin sensitivity and adiposity before and after these hormone medications. The outcomes that will be measured are: 1) insulin sensitivity, 2) hormone levels (total and free testosterone levels, sex hormone-binding globulin levels) and 3) body composition and abdominal adiposity.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
  • Aging
  • Insulin Resistance
  • Drug: Testosterone
    Testosterone gel
  • Drug: Estrogen
    Estrogen patch
  • Experimental: Arm 1
    +Testosterone, +Estrogen
    Interventions:
    • Drug: Testosterone
    • Drug: Estrogen
  • Experimental: Arm 2
    +Testosterone, -Estrogen
    Intervention: Drug: Testosterone
  • Experimental: Arm 3
    -Testosterone, +Estrogen
    Intervention: Drug: Estrogen
  • No Intervention: Arm 4
    -Testosterone, -Estrogen
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
February 2014
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • males age 60-85 years
  • non-diabetic fasting glucose and 2-hour oral glucose tolerance test (OGTT)
  • overall good general medical health and signed informed consent
  • willing to travel to West LA VA and UCLA in Los Angeles, CA

Exclusion Criteria:

  • any clinically significant abnormalities detected on screening physical exam or laboratory testing (e.g. PSA > 4)
  • or other symptom or history of a significant underlying medical or psychiatric illness
  • BMI < 20 or > 40
  • subjects already on testosterone therapy or medications that might influence glucose regulation or hormone levels
  • subjects with a history of deep venous thromboses, pulmonary embolism, breast cancer, prostate cancer, polycythemia or other contraindications to estrogen or testosterone
Male
60 Years to 85 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00680797
ARCD-034-04F
Yes
Department of Veterans Affairs
Department of Veterans Affairs
Not Provided
Principal Investigator: Cathy Lee, PhD VA Greater Los Angeles Healthcare System, West LA
Department of Veterans Affairs
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP